< em > The Future of Schizophrenia Psychopharmacotherapy < /em > : More Antipsychotic Atypicality? Guess So!

Psychopharmacol Bull. 2023 Feb 28;53(1):55-57.ABSTRACTNo single neurotransmitter aberration could explain the heterogeneity of schizophrenia syndrome and thus, treatment strategies capitalizing solely on a single neurotransmitter system (e.g., DA blockade) is less likely to be fully successful on clinical grounds. Hence, there is a pressing need to develop newer antipsychotics above and beyond DA antagonism. In this regard, authors brief on five agents that sound pretty promising and might usher in a new sparkle in the psychopharmacotherapy of schizophrenia. This paper is a sequel for authors' previous article on future of schizophrenia psychopharmacotherapy.PMID:36873922 | PMC:PMC9981338
Source: Psychopharmacology Bulletin - Category: Psychiatry & Psychology Authors: Source Type: research